Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2026 financi

Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right

Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and

Eastern Bank raised its position in shares of Royalty Pharma PLC (NASDAQ: RPRX) by 2.0% in the third

Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annu

Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 15 years by 4.89% on an annua

Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown

TD Cowen analyst Michael Nedelcovych maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises

Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impac

Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 27.34% on an annu

Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annu

Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA

JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raise

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.32 per share which beat the analyst c

U.S. stock futures higher, AstraZeneca dips on merger talks, Apple down 7.4%, other stocks moving lo

Neurimmune announced today that it has sold a portion of its royalty interest in cliramitug to Royal

TD Cowen analyst Steve Scala maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the pri

Teva will advance TEV-'408 into a Phase 2b vitiligo study after Phase 1b data showed skin pigmen

Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expandin

Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the

JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raise

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.30 per share which beat the analyst c

Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and

Royalty Pharma plc (NASDAQ:RPRX) today announced a research and development (R&D) co-funding agr

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with rep

Zymeworks Inc. (NASDAQ:ZYME) and Royalty Pharma plc (NASDAQ:RPRX) today announced an agreement for $

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.47 per share which beat the analyst c

Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the

Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being

Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including re

Royalty Pharma plc (NASDAQ:RPRX) today announced that its board of directors has declared a dividend

Pharmaceuticals giant, Merck & Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer dr

Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfr

Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired the final portion of PTC Thera

Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired a pre-existing royalty interes

TD Cowen analyst Steve Scala maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the pri

FDA placed hold on Denali's drug for Pompe disease, requesting changes to protocol. No additiona

Denali Therapeutics Inc. (NASDAQ:DNLI) and Royalty Pharma plc (NASDAQ:RPRX) today announced a $275 m

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investo

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.17 per share which beat the analyst c

Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired a royalty interest in Alnylam&

Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and

Goldman Sachs analyst Asad Haider initiates coverage on Royalty Pharma (NASDAQ:RPRX) with a Buy